Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VS-105 in Healthy and Hemodialysis Subjects
NCT03043482Phase 1Completed
- Sponsor
- Vidasym
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CK15 in secondary hyperparathyroidism (SHPT) (3 arms), sponsored by Vidasym. Primary endpoints: Safety and tolerability (numbers and percentages of adverse events) at 3 weeks, Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration up to 16 days and 4 more. Started Jan 2017; status: completed.
02
Drugs
CK15
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03043482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043482.